These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Cisplatin, etoposide, and vincristine combination chemotherapy in the treatment of non-small cell lung cancer.
    Author: Watanabe A, Ichiyama S, Shimokata K, Nagura E, Saito H, Saka H, Nomura F, Sakai S, Saito H.
    Journal: Nagoya J Med Sci; 1993 Mar; 55(1-4):41-6. PubMed ID: 8247105.
    Abstract:
    Thirty patients with previously untreated, inoperable non-small cell lung cancer (NSCLC) were treated with cisplatin, etoposide and vincristine. Among twenty-nine evaluable patients, eight patients achieved partial response and the overall response rate was 28%. No patient achieved a complete response. The median survival time was 51 weeks. Myelosuppression was the dose-limiting toxicity. Four patients had a leukocyte nadir of less than 1000/mm3, and one died from severe myelosuppression and sepsis. The other toxicities were nausea/vomiting, peripheral neuropathy, and alopecia. We conclude that cisplatin, etoposide, and vincristine combination chemotherapy offers moderate activity for inoperable non-small cell lung cancer.
    [Abstract] [Full Text] [Related] [New Search]